<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00570726</url>
  </required_header>
  <id_info>
    <org_study_id>07.10</org_study_id>
    <nct_id>NCT00570726</nct_id>
  </id_info>
  <brief_title>Treatment of Failing Blebs With Ranibizumab</brief_title>
  <official_title>Effect of Needle Bleb Revision With Ranibizumab as a Primary Intervention in a Failing Bleb Following Trabeculectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The New York Eye &amp; Ear Infirmary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The New York Eye &amp; Ear Infirmary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to evaluate the efficacy and safety in the use of Ranibizumab, an&#xD;
      effective vascular endothelial growth factor (VGEF) inhibitor, in treating patients with a&#xD;
      failing bleb, characterized by increased fibrosis and vascularization of the conjuctiva,&#xD;
      following trabeculectomy. Six subjects from one site will be enrolled in this study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <condition>Failing Bleb Following Trabeculectomy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab (Lucentis)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to provide written informed consent and comply with study assessments for the&#xD;
             full duration of the study&#xD;
&#xD;
          -  Age &gt; 40 years&#xD;
&#xD;
          -  Patients with Open-angle Glaucoma who have had trabeculectomy&#xD;
&#xD;
          -  Patients determined to have failing bleb with presence of superficial bleb vascularity&#xD;
             and IOP increase on 3 successive visits without topical medication&#xD;
&#xD;
          -  Patients whose intraocular pressure (IOP) is above goal IOP after suture lysis and&#xD;
             digital compression have been attempted&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy (positive pregnancy test) or lactation.&#xD;
&#xD;
          -  Premenopausal women not using adequate contraception. The following are considered&#xD;
             effective means of contraception: surgical sterilization or use of oral&#xD;
             contraceptives, barrier contraception with either a condom or diaphragm in conjunction&#xD;
             with spermicidal gel, an IUD, or contraceptive hormone implant or patch.&#xD;
&#xD;
          -  Current infection or inflammation in either eye&#xD;
&#xD;
          -  Any abnormality preventing reliable applanation tonometry in either eye&#xD;
&#xD;
          -  Other non-glaucomatous disease affecting visual field, (pituitary lesions,&#xD;
             demyelinating disease, congenital optic nerve anomaly, prior retinal and optic nerve&#xD;
             vascular occlusive disease, retinal dystrophy and degeneration, diabetes and HIV and&#xD;
             AIDS infection)&#xD;
&#xD;
          -  Strabismus, nystagmus, monocular patient&#xD;
&#xD;
          -  Prior enrollment in the study&#xD;
&#xD;
          -  Any other condition that the investigator believes would pose a significant hazard to&#xD;
             the subject if the investigational therapy were initiated&#xD;
&#xD;
          -  Participation in another simultaneous medical investigation or trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Liebmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Robert Ritch, MD, LLC.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glaucoma Associates of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>December 9, 2007</study_first_submitted>
  <study_first_submitted_qc>December 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2007</study_first_posted>
  <last_update_submitted>October 14, 2014</last_update_submitted>
  <last_update_submitted_qc>October 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2014</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

